hydroxychloroquine has been researched along with Neoplasm Metastasis in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 7.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| " We evaluated hydoxychloroquine (HCQ), an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice." | 6.79 | Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. ( Chan, JA; Cleary, JM; Enzinger, PC; Fuchs, CS; Killion, L; Kimmelman, AC; Mamon, H; McCleary, NJ; Meyerhardt, JA; Ng, K; Rubinson, DA; Schrag, D; Sikora, AL; Spicer, BA; Wang, X; Wolpin, BM, 2014) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 3.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| " We evaluated hydoxychloroquine (HCQ), an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice." | 2.79 | Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. ( Chan, JA; Cleary, JM; Enzinger, PC; Fuchs, CS; Killion, L; Kimmelman, AC; Mamon, H; McCleary, NJ; Meyerhardt, JA; Ng, K; Rubinson, DA; Schrag, D; Sikora, AL; Spicer, BA; Wang, X; Wolpin, BM, 2014) |
| "Sec62 promotes GC metastasis by activating autophagy and subsequently regulating TIMP-1 and MMP2/9 balance." | 1.72 | Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation. ( Chu, Y; Jiang, MZ; Jin, YR; Li, XF; Liang, J; Lin, JC; Shi, YT; Su, S; Wu, N; Xu, B; Zhou, H, 2022) |
| "Twenty-five stage IV cancer patients were identified." | 1.42 | Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. ( Chi, KH; Chi, MS; Kao, SJ; Ko, HL; Lee, CY; Yang, KL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Su, S | 1 |
| Shi, YT | 1 |
| Chu, Y | 1 |
| Jiang, MZ | 1 |
| Wu, N | 1 |
| Xu, B | 1 |
| Zhou, H | 1 |
| Lin, JC | 1 |
| Jin, YR | 1 |
| Li, XF | 1 |
| Liang, J | 1 |
| Chen, X | 1 |
| Yu, Q | 1 |
| Liu, Y | 1 |
| Sheng, Q | 1 |
| Shi, K | 1 |
| Wang, Y | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| He, Q | 1 |
| Bui, AN | 1 |
| Hirner, J | 1 |
| Singer, SB | 1 |
| Eberly-Puleo, A | 1 |
| Larocca, C | 1 |
| Lian, CG | 1 |
| LeBoeuf, NR | 1 |
| Wolpin, BM | 1 |
| Rubinson, DA | 1 |
| Wang, X | 1 |
| Chan, JA | 1 |
| Cleary, JM | 1 |
| Enzinger, PC | 1 |
| Fuchs, CS | 1 |
| McCleary, NJ | 1 |
| Meyerhardt, JA | 1 |
| Ng, K | 1 |
| Schrag, D | 1 |
| Sikora, AL | 1 |
| Spicer, BA | 1 |
| Killion, L | 1 |
| Mamon, H | 1 |
| Kimmelman, AC | 1 |
| Chi, KH | 1 |
| Ko, HL | 1 |
| Yang, KL | 1 |
| Lee, CY | 1 |
| Chi, MS | 1 |
| Kao, SJ | 1 |
| Patel, S | 1 |
| Hurez, V | 1 |
| Nawrocki, ST | 1 |
| Goros, M | 1 |
| Michalek, J | 1 |
| Sarantopoulos, J | 1 |
| Curiel, T | 1 |
| Mahalingam, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer[NCT01273805] | Phase 2 | 20 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2-month progression-free survival rate was defined as the percentage of patients absent progression (PD) or death before 2 months. Patients were considered to have experienced PD if they demonstrated either clinical deterioration resulting in withdrawal or PD per RECIST 1.0 criteria: At least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and at the first restaging at 2 months.
| Intervention | percentage of patients (Number) |
|---|---|
| Hydroxychloroquine 400 mg b.i.d. | 10 |
| Hydroxychloroquine 600 mg b.i.d. | 10 |
All grade 4-5 adverse events with treatment attribution of possibly, probably or definite based on CTCAEv3 as reported on case report forms. (NCT01273805)
Timeframe: Adverse events were assessed each cycle throughout treatment. Participants were followed for the duration of treatment, an average of 34 days for this study population.
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxychloroquine 400 mg b.i.d. | 0 |
| Hydroxychloroquine 600 mg b.i.d. | 0 |
Overall survival estimated using Kaplan-Meier (KM) methods is defined as the time from study entry to death or date last known alive. (NCT01273805)
Timeframe: All patients were followed until death. Median survival follow-up in this study cohort was 60 days (95% CI: 40-184).
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine 400 mg b.i.d. | 51.5 |
| Hydroxychloroquine 600 mg b.i.d. | 83 |
Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to time of objective progression on CT scan or the time of death for patients with clinical deterioration resulting in withdrawal from the trial. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. Patients without an event were censored at date of last disease evaluation. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and every 2 months on treatment. Median PFS follow-up in this study cohort was 46.5 days (95% CI 33-61).
| Intervention | days (Median) |
|---|---|
| Hydroxychloroquine 400 mg b.i.d. | 51.5 |
| Hydroxychloroquine 600 mg b.i.d. | 44.5 |
Tumor response rate is the percentage of patients achieving complete or partial response on treatment based on RECIST 1.0 criteria. For target lesions, complete response (CR) is disappearance of all target lesions and partial response (PR) is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. CR for the evaluation of non-target lesions is the disappearance of non-target lesions and normalization of tumor marker level. Appearance of one or more new lesions is classified as progression of non-target lesions. CR or PR confirmation is required >/= 4 weeks. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and every 2 months on treatment. Median duration of treatment for this study cohort was 34 days.
| Intervention | percentage of patients (Number) |
|---|---|
| Hydroxychloroquine 400 mg b.i.d. | 0 |
| Hydroxychloroquine 600 mg b.i.d. | 0 |
1 trial available for hydroxychloroquine and Neoplasm Metastasis
| Article | Year |
|---|---|
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease-Free Sur | 2014 |
5 other studies available for hydroxychloroquine and Neoplasm Metastasis
| Article | Year |
|---|---|
Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Autophagy; Cell Line, Tumor; eIF-2 Kinase; Female; Humans; | 2022 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Duct | 2019 |
De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Antimalarials; Combined Modality Therapy; Ex | 2021 |
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Re | 2015 |
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color | 2016 |